SCHEMBL802703

SCHEMBL802703

c1ccc(-c2cc(-c3ccccc3)nc(-n3c4ccccc4c4cc5c(cc43)C3(c4ccccc4-c4ccccc43)c3ccccc3-5)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
NPSR1 Q6W5P4 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
AGTR1 P30556 2/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
TDP1 Q9NUW8 2/20 0.34
LMNA P02545 2/20 0.34
MAPK10 P53779 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 3/20 0.32
HPGD P15428 3/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20199502 0.99 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL24078426 0.98 MAPT (0.33) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL25121717 0.96 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL25121523 0.95 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL802667 0.94 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL20199790 0.94 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL20199475 0.94 MAPT (0.35) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL25121554 0.93 MAPT (0.33) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL20199448 0.93 MAPT (0.34) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9
SCHEMBL18119713 0.93 MAPT (0.31) MAPTSMN1; SMN2NPSR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230320113-A1 Light Emitting Device and Composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-10-05 US disclosed
US-20230108986-A1 ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2023-04-06 US disclosed
US-10954403-B2 Ink composition of an organic functional material MERCK PATENT GMBH (DE) 2021-03-23 US disclosed
US-20180212159-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
US-20180212159-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
WO-2017102061-A1 INK COMPOSITION OF AN ORGANIC FUNCTIONAL MATERIAL MERCK PATENT GMBH (DE) 2017-06-22 WO disclosed
US-9126970-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-09-08 US disclosed
US-9126970-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-09-08 US disclosed
US-20120068170-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-03-22 US disclosed
US-20120068170-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-03-22 US disclosed
WO-2010136109-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120068170-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES SLCO2B1, SLCO1B3, SLCO4C1 MAPT 1399/4885SMN1; SMN2 4462/4885NPSR1 4435/4885
US-20180212159-A1 ORGANIC ELECTROLUMINESCENT ELEMENT EML4, EPCAM, L1CAM MAPT 988/4885SMN1; SMN2 3568/4885NPSR1 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.